Antag Therapeutics' Obesity Drug Shows Positive Early Trial Results

Antag Therapeutics announced favorable Phase 1 trial data for its GIPR antagonist, AT7687, targeting obesity and cardiometabolic conditions. The study indicated a good safety profile and potential for once-weekly dosing. Preclinical findings also suggested additional benefits when combined with another compound, with a Phase 2a trial expected soon.